Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Close this search box.

White Papers

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

CROs at the high table of drug discovery

Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.

CMOs bask in pill promise

With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.

Pharma 4.0: Taking CDMO factories by storm

Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.

New modalities hog the limelight

Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.

Bioanalytical outsourcing soars as drugs grow more complex

Outsourcing of bioanalytical lab services is set for explosive growth as the increasingly complex nature of modern-day therapeutics makes partnerships with CROs indispensable.

Net-zero pledge: CDMOs go greener

A number of CDMOs are accelerating their environmental drive as sustainability goals become one of the most urgent business strategies facing pharma companies today.

Powering up antibody-drug conjugates with PROTACS

Read this White Paper on the ADC alternative that is capturing scientists’ imagination – antibody-linked PROTACs and the impact it could have in oncology, neurology, virology, and agriculture.

Cracking the Code: The transformative role of pDNA in Cell and Gene therapy

Read this article to understand the rise in demand for pDNA and what to look for in a pDNA engineering and manufacturing partner when deciding to outsource.

Integrated or Standalone: How the industry thinks about drug development outsourcing

Read this white paper to gain insights about perceptions around integrated and standalone outsourcing. The white paper is based on surveys conducted across emerging biopharma, mid-size and large pharma in North America, Europe and other regions.

Hyaluronic Acid - A wonder molecule for the cosmetic and pharma industries

Understanding the many application areas of Hyaluronic acid in the cosmetic and pharma space, including possibilities for the future.

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy, Cookies Policy and .

To view or email, Please share your details view

To download, Please share your details